A feasibility study to assess the accuracy of indocyanine green in the identification of sentinel lymph nodes for patients with cutaneous melanoma

Registry ID

EUCTR2012-002244-25

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Norfolk & Norwich University Hospital

Start date

2012-07-05

Completion date

2013-02-11

Last update

2026-08-16

Conditions

• Cutaneous Melanoma

Summary

The principal research question is to assess the sensitivity of indocyanine green (ICG) for Sentinel lymph node detection in cutaneous melanoma in combination with technetium radio­isotope and patent blue dye.

Locations

• , , UK

Related clinical trials

• A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
• Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
• Phase 1 Study of PF-08046033 in Advanced Solid Tumors
• NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
• Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

View on source registry